Related Experiment Video
Updated: Jun 27, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Postconditioning cardioprotection against infarct size and post-ischemic systolic dysfunction is influenced by gender
Claudia Penna1, Francesca Tullio, Annalisa Merlino
1Dip. to di Scienze Cliniche e Biologiche, Università di Torino, Regione Gonzole 10, 10043, Orbassano, TO, Italy.
Insights
Cardioprotection by postconditioning (PostC) shows gender differences in reducing infarct size and systolic dysfunction after ischemia. PostC benefits females more for systolic function, suggesting an anti-necrotic rather than anti-stunning effect.
Area of Science:
- Cardiovascular Physiology
- Ischemic Heart Disease Research
- Gender-Specific Medicine
Background:
- Cardioprotection strategies aim to limit heart damage during ischemia-reperfusion injury.
- The gender-specific effects of postconditioning (PostC) on myocardial infarct size (IS) and post-ischemic systolic dysfunction (PSD) remain unclear.
Purpose of the Study:
- To investigate whether the cardioprotective effects of PostC are dependent on gender.
- To evaluate the impact of PostC on reducing IS and PSD in male and female rat hearts subjected to varying ischemia durations.
Main Methods:
- Isolated male and female rat hearts underwent global ischemia (10 or 30 minutes) followed by reperfusion (120 minutes).
- Postconditioning was applied immediately after ischemia, consisting of 5 cycles of 10-second reperfusion/ischemia.
- Infarct size (IS) and post-ischemic systolic dysfunction (PSD) were assessed. Contracture development and buffer perfusion effects were also monitored.
Main Results:
- After 10-min ischemia, female hearts showed greater IS and PSD; PostC attenuated both in females only.
- After 30-min ischemia, female hearts had smaller IS, but similar PSD compared to males.
- PostC reduced IS in both genders (less effective in females) and PSD in females but not males. Contracture correlated with IS.
Conclusions:
- Myocardial IS, contracture, and PSD are differentially affected by gender based on ischemia duration.
- The reduction in IS by PostC is dependent on the extent of index-ischemia.
- PostC's improvement of systolic function is primarily due to its anti-necrotic effects, particularly evident in females.
Abstract:
Whether cardioprotection by postconditioning (PostC) is gender dependent is not clear. We studied the effect of PostC in terms of both infarct size (IS) and post-ischemic systolic dysfunction (PSD) reduction. Isolated male and female rat hearts were subjected to 10- or 30-min of global ischemia and 120-min of reperfusion, with or without PostC (i.e., 5 cycles of 10-s reperfusion/ischemia immediately after the ischemia). Surprisingly, after 10-min ischemia, IS and PSD were greater in female than male hearts (IS: 21 +/- 2% Vs. 11 +/- 2%; P < 0.01), while PostC attenuated IS and PSD in female hearts only. After 30-min ischemia IS was smaller in female than male hearts (52 +/- 2% Vs. 61 +/- 3%; P < 0.05), whereas PSD was similar in these two groups. PostC reduced IS in both genders, though the effect was smaller (P < 0.05) in females. Yet, PostC reduced PSD in female, but not in male hearts. Contracture development paralleled IS in all groups. To check the effects of buffer perfusion over heart function, additional hearts underwent 150-min buffer perfusion only. Contractile function of these hearts was not significantly affected over time. In conclusion IS, contracture and PSD are differently affected by gender, depending on ischemia duration. Yet, reduction of IS induced by PostC depends on the extension of IS induced by index-ischemia. While in female hearts reduction of PSD paralleled IS reduction, in male it does not occur. Results suggest that improvement of systolic function is mainly due to the anti-necrotic rather than to the anti-stunning effect exerted by PostC.
Related Concept Videos
Pathophysiology of Cardiac Performance
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
